Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

IMMUNOCAN

Financiado

Cerrado

Toward enhancing activities of European institutions in the FDUSCC IM cancer res...

Toward enhancing activities of European institutions in the FDUSCC IM cancer research joint institute in China The joint institute Fudan University Shanghai Cancer Centre – Institut Mérieux laboratory (FDUSCC-IM), created in May 2010, is conducting ambitious scientific research projects on oncology in China. Its 2 founding partners, Fudan... ver más

31/12/2015

2M€

Presupuesto del proyecto: 2M€

Líder del proyecto

TRANSGENE SA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 5 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2015-12-31 No tenemos la información de la convocatoria

0% 96% 100%

Características del participante

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

5 Participantes

0.00€ | Lider

MHH

N.D. | Participante

UCPH

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

TRANSGENE SA No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 2M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto The joint institute Fudan University Shanghai Cancer Centre – Institut Mérieux laboratory (FDUSCC-IM), created in May 2010, is conducting ambitious scientific research projects on oncology in China. Its 2 founding partners, Fudan University (China) and Transgene (part of Institut Mérieux, France) wish to increase their translational medical research cooperation with European countries. In a first step, collaboration will enlarge to an active partnership with Danish, Italian and German teams, with the following objectives: (i) increase the EU-China knowledge exchanges in the field of cancer prognosis – by organizing in China summer schools, seminars and international conferences, as well as by hosting PhDs and post PhD research fellows in the joint institute, (ii) enhance the research capacity and the technological transfer to the joint institute – by providing adequate human resources and equipment to conduct beyond the state-of-the-art oncology research, (iii) promote a reference Euro-Asian centre on Chinese cancer prognosis – by spreading the knowledge and by raising awareness in China and European Union. Research activities will be held in China in collaboration with the new European partners, in order to enhance current research activities of the joint institute and to create durable links between Chinese and European teams. Current research is focused on immune phenotype as personalized medical biomarker for prognosis of Chinese cancer patients, and will be extended to new types of cancer and biomarkers. These prognosis studies will help to guide clinical decision-making by facilitating the selection of appropriate treatment options. Ultimately, this FP7 INCOLAB is an opportunity to build a Euro-Asian reference centre for medical and scientific research on cancer and to extend the already existing cooperation between the FDUSCC-IM laboratory and Europe by considering the opening of the joint institute to additional European member.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores